Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools
In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of their extensive catalogue of research tools.